BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 7691252)

  • 1. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
    Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.
    Soiffer RJ; Weller E; Alyea EP; Mauch P; Webb IL; Fisher DC; Freedman AS; Schlossman RL; Gribben J; Lee S; Anderson KC; Marcus K; Stone RM; Antin JH; Ritz J
    J Clin Oncol; 2001 Feb; 19(4):1152-9. PubMed ID: 11181681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
    Soiffer RJ; Ritz J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.
    Sugita K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
    Transplantation; 1994 May; 57(10):1465-73. PubMed ID: 7910987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation.
    Fujimaki K; Maruta A; Yoshida M; Kodama F; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
    Bone Marrow Transplant; 2001 Jun; 27(12):1275-81. PubMed ID: 11548845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
    Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium.
    Roy DC; Tantravahi R; Murray C; Dear K; Gorgone B; Anderson KC; Freedman AS; Nadler LM; Ritz J
    Blood; 1990 Jan; 75(1):296-304. PubMed ID: 1967216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
    Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
    Bone Marrow Transplant; 1994 Feb; 13(2):181-5. PubMed ID: 7515741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT).
    Nagler A; Rabinowitz R; Rosengolts-Rat J; Condiotti R; Schlesinger M
    J Hematother Stem Cell Res; 2000 Feb; 9(1):63-75. PubMed ID: 10738973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation.
    Imamura M; Tsutsumi Y; Miura Y; Toubai T; Tanaka J
    Hematology; 2003 Feb; 8(1):19-26. PubMed ID: 12623423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.